COHERUS.COM: Keyword Density Checker

Total words: 1229 | 2-word phrases: 321 | 3-word phrases: 341 | 4-word phrases: 344

PAGE INFO

Title	Try to keep the title under 60 characters (54 characters) Coherus BioSciences \| Novel Immunotherapies for Cancer
Description	Try to keep the meta description between 50 - 160 characters (156 characters) Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of novel immunotherapies to treat cancer.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (46 characters) Empowering innovation. Delivering opportunity.

ONE WORD PHRASES 223 Words

#	Keyword	Frequency	Density
1	our	12	5.38%
2	of	11	4.93%
3	the	7	3.14%
4	clinical	7	3.14%
5	coherus	7	3.14%
6	pipeline	6	2.69%
7	a	6	2.69%
8	patient	6	2.69%
9	immunooncology	5	2.24%
10	and	5	2.24%

TWO WORD PHRASES 321 Words

#	Keyword	Frequency	Density
1	2024 coherus	5	1.56%
2	clinical trials	4	1.25%
3	patient advocacy	3	0.93%
4	our pipeline	3	0.93%
5	pipeline our	3	0.93%
6	learn more	3	0.93%
7	oncology therapeutics	3	0.93%
8	coherus biosciences	3	0.93%
9	filings corporate	2	0.62%
10	job openings	2	0.62%
11	shareholder services	2	0.62%
12	of directors	2	0.62%
13	il27 chs114	2	0.62%
14	ccr8 chs1000	2	0.62%
15	board of	2	0.62%
16	trials careers	2	0.62%
17	careers our	2	0.62%
18	our culture	2	0.62%
19	culture job	2	0.62%
20	logo white	2	0.62%

THREE WORD PHRASES 341 Words

#	Keyword	Frequency	Density
1	2024 coherus biosciences	3	0.88%
2	clinical trials careers	2	0.59%
3	services medical information	2	0.59%
4	medical information support	2	0.59%
5	pipeline toripalimabtpzi pd1	2	0.59%
6	toripalimabtpzi pd1 casdozokitug	2	0.59%
7	pd1 casdozokitug il27	2	0.59%
8	casdozokitug il27 chs114	2	0.59%
9	ilt4 clinical trials	2	0.59%
10	trials careers our	2	0.59%
11	patient support services	2	0.59%
12	careers our culture	2	0.59%
13	our culture job	2	0.59%
14	corporate overview press	2	0.59%
15	overview press releases	2	0.59%
16	press releases eventspresentations	2	0.59%
17	sec filings corporate	2	0.59%
18	filings corporate governance	2	0.59%
19	board of directors	2	0.59%
20	support services medical	2	0.59%
21	culture job openings	2	0.59%
22	leadership partnering patient	2	0.59%
23	partnering patient advocacy	2	0.59%
24	about us leadership	2	0.59%
25	scientific posters medicines	2	0.59%
26	therapeutics scientific posters	2	0.59%
27	oncology therapeutics scientific	2	0.59%
28	us leadership partnering	2	0.59%
29	effectiveness of our	1	0.29%
30	or as a	1	0.29%

FOUR WORD PHRASES 344 Words

#	Keyword	Frequency	Density
1	trials careers our culture	2	0.58%
2	oncology therapeutics scientific posters	2	0.58%
3	our culture job openings	2	0.58%
4	careers our culture job	2	0.58%
5	clinical trials careers our	2	0.58%
6	ilt4 clinical trials careers	2	0.58%
7	pd1 casdozokitug il27 chs114	2	0.58%
8	toripalimabtpzi pd1 casdozokitug il27	2	0.58%
9	pipeline toripalimabtpzi pd1 casdozokitug	2	0.58%
10	services medical information support	2	0.58%
11	overview press releases eventspresentations	2	0.58%
12	patient support services medical	2	0.58%
13	sec filings corporate governance	2	0.58%
14	therapeutics scientific posters medicines	2	0.58%
15	support services medical information	2	0.58%
16	corporate overview press releases	2	0.58%
17	us leadership partnering patient	2	0.58%
18	about us leadership partnering	2	0.58%
19	leadership partnering patient advocacy	2	0.58%
20	our io drug candidates	1	0.29%
21	io drug candidates we	1	0.29%
22	all 06052024 coherus biosciences	1	0.29%
23	view all 06052024 coherus	1	0.29%
24	drug candidates we have	1	0.29%
25	across a range of	1	0.29%
26	of our io drug	1	0.29%
27	effectiveness of our io	1	0.29%
28	upfront all cash transaction	1	0.29%
29	million upfront all cash	1	0.29%
30	multiple ongoing clinical trials	1	0.29%
31	ongoing clinical trials across	1	0.29%
32	clinical trials across a	1	0.29%
33	trials across a range	1	0.29%
34	coherus biosciences announces divestiture	1	0.29%
35	40 million upfront all	1	0.29%
36	a 40 million upfront	1	0.29%
37	06272024 coherus biosciences announces	1	0.29%
38	a range of cancer	1	0.29%
39	range of cancer indications	1	0.29%
40	assessing our investigational immunooncology	1	0.29%

EXTERNAL LINKS

#	URL	Whois	Check
1	https://iitrequests-coherus.icc.solutions.iqvia.com/IIT/Default.aspx	Whois	iqvia.com
2	https://grants-coherus.icc.solutions.iqvia.com/RMS/Default.aspx	Whois	iqvia.com
3	https://www.linkedin.com/company/coherus-biosciences	Whois	linkedin.com
4	https://twitter.com/coherus_bio?lang=en	Whois	twitter.com
5	https://22fillmore.com/	Whois	22fillmore.com